History
  • No items yet
midpage
United States Ex Rel. Schumann v. Astrazeneca Pharmaceuticals L.P.
2014 U.S. App. LEXIS 20116
| 3rd Cir. | 2014
Read the full case

Background

  • Schumann, a qui tam relator under the FCA, sues BMS and AZ for allegedly false best-price reporting and related kickbacks to Medco.
  • The District Court dismissed the CFAC for lack of subject matter jurisdiction under the FCA's public disclosure bar, finding Schumann not an original source.
  • Schumann alleged that he learned of the schemes through his Medco position, reviewing confidential agreements and discussing them with company officials.
  • BMS allegedly paid data fees and rebates to Medco to secure Coumadin exclusive distribution and to influence Medco’s pricing and best-price reporting.
  • AZ allegedly paid rebates and other payments to Medco and plans managed by Medco to favor Prilosec and Nexium, while omitting those payments from best-price reports.
  • The court later denied Schumann’s motions to reconsider and to amend, but concluded amendments would be futile and dismissed with prejudice.

Issues

Issue Plaintiff's Argument Defendant's Argument Held
Whether Schumann is an original source for BMS claims Schumann asserts direct, independent knowledge from Medco documents and dealings. Knowledge derived from others’ documents is not direct or independent. Schumann not an original source for BMS claims.
Whether Schumann is an original source for AZ claims Schumann relies on Medco/AZ documents and discussions to show direct knowledge. Knowledge from documents and others’ discussions is not direct or independent. Schumann not an original source for AZ claims.
Whether the district court properly dismissed for lack of subject matter jurisdiction Original source exception preserves jurisdiction despite public disclosures. Public disclosures bar jurisdiction absent an original source. District Court correct; lack of original source bars jurisdiction.
Whether the district court properly denied reconsideration and leave to amend Supplemental declarations show new facts to support original-source status. New evidence cannot be used to create original-source status after dismissal; futile to amend. Court did not abuse discretion; amendments futile and reconsideration denied.

Key Cases Cited

  • Paranich v. Sorgnard, 396 F.3d 326 (3d Cir. 2005) (public disclosure bar and original-source framework for FCA)
  • Stinson, Lyons, Gerlin & Bustamante, P.A. v. Prudential Ins. Co., 944 F.2d 1149 (3d Cir. 1991) (definition of direct and independent knowledge under original-source rule)
  • Dunleavy v. Cnty. of Del., 123 F.3d 734 (3d Cir. 1997) (original-source framework and FCA context)
  • Atkinson v. Pa. Shipbuilding Co., 473 F.3d 506 (3d Cir. 2007) (explication of direct and independent knowledge under § 3730(e)(4)(B))
  • Springfield Terminal Ry. Co. v. Quinn, 14 F.3d 645 (D.C. Cir. 1994) (fraud disclosure inference structure for original-source analysis)
  • Mistick PBT v. Housing Auth. of City of Pitt., 186 F.3d 376 (3d Cir. 1999) (limits on relator knowledge when derived from public disclosures)
  • Zizic v. Q2Administrators, LLC, 728 F.3d 228 (3d Cir. 2013) (relevant standards for independent knowledge in original-source analysis)
  • Rockwell Int’l Corp. v. United States, 549 U.S. 457 (S. Ct. 2007) (relation of original-source requirement to jurisdiction under FCA)
  • Vuyyuru v. Jadhav, 555 F.3d 337 (4th Cir. 2009) (limits on relator’s independent knowledge theory)
Read the full case

Case Details

Case Name: United States Ex Rel. Schumann v. Astrazeneca Pharmaceuticals L.P.
Court Name: Court of Appeals for the Third Circuit
Date Published: Oct 20, 2014
Citation: 2014 U.S. App. LEXIS 20116
Docket Number: 13-1489
Court Abbreviation: 3rd Cir.